The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Medicare Changes Could Have Some Patients Paying More for Drugs

Medicare Changes Could Have Some Patients Paying More for Drugs

January 15, 2019 • By Lisa Rapaport

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—A proposed shift in Medicare coverage for medicines administered by doctors may help reduce total drug spending, but a new study suggests it may also lead to higher out-of-pocket costs for some patients.

You Might Also Like
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
  • Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs
  • Complex Patients More Likely to Switch from Medicare Advantage

Right now, drugs given by infusion or injection in outpatient settings are covered by Medicare Part B, which is part of the original Medicare program. In a push to curb health spending, the Trump administration has proposed moving coverage for many of these physician-administered medicines to standalone drug plans, known as Medicare Part D, which typically contract with pharmacies to fill prescriptions for consumers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Currently, Medicare Part B does not actively negotiate drug prices. The idea underlying this policy proposal is that plans in Part D have negotiating power that will help drive total spending down compared to Part B,” study coauthor Nina Jain, MD, of Brigham and Women’s Hospital, Boston, tells Reuters Health by email.

To see how the proposal may impact total drug spending and patients’ out-of-pocket costs, researchers examined data on the 75 brand-name prescription drugs associated with the highest Part B spending among fee-for-service Medicare members in 2016.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

These 75 drugs accounted for $19.8 billion—or $21.6 billion at 2018 prices, researchers reported Jan. 14 online in JAMA Internal Medicine.1 Under the proposed policy change, the researchers estimate, total Part D spending would be $17.6 billion to $20.1 billion, after rebates to insurers and pharmacy benefit managers.

This means moving coverage from Part B to Part D may correspond with roughly a 7–18% decrease in drug spending, the analysis found.

However, savings may be limited by several brand-name drugs that are in a protected class that must be covered by insurance. This includes certain physician-administered antipsychotics, anticonvulsants, antidepressants and antiretrovirals.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“About 40% of the drugs we studied were in a protected class,” Jain says. “Part D plans must cover most drugs in protected classes, limiting plans’ ability to negotiate lower prices for these drugs.”

Overall, shifting coverage from Part B to Part D would decrease median out-of-pocket costs for patients by $860.

But patients who purchase Medigap plans to cover co-payments and deductibles not covered by Part B may find their out-of-pocket costs rise.

For people with Medigap insurance, estimated out-of-pocket costs would rise by a median of $1,460 for those with Part D coverage and by a median of $1,952 for those without Part D coverage.

One limitation of the study is that it didn’t account for how the proposed changes might impact insurance premiums or medication use, the study authors note. It also only examined fee-for-service Medicare, and didn’t look at what would happen with people in other types of plans, such as Medicare HMOs.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: drug costs, Medicare, Medicare Part B, Medicare Part D

You Might Also Like:
  • High Cost of DMARDs Could Limit Medicare Patients’ Treatment Adherence
  • Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs
  • Complex Patients More Likely to Switch from Medicare Advantage
  • Unwelcome News about Medicare’s Rising Drug Plan Costs

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)